Success Metrics

Clinical Success Rate

83.3%

Based on 5 completed trials

Completion Rate

83%(5/6)

Active Trials

0(0%)

Results Posted

120%(6 trials)

Terminated

1(17%)

Phase Distribution

Ph phase_1

100%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution6 total trials

Phase 1Safety & dosage

6(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

83.3%

5 of 6 finished

Non-Completion Rate

16.7%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(5)

Terminated(1)

Detailed Status

Completed5

Terminated1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

83.3%

Most Advanced

Phase 1

Trials by Phase

Phase 16 (100.0%)

Trials by Status

completed583%

terminated117%

Recent Activity

0 active trials

Showing 5 of 6

completedphase_1

A Study of the Absorption, Distribution, Metabolism and Excretion of LY3039478 in Healthy Participants

NCT02917733

completedphase_1

Study of LY3039478 in Healthy Participants

NCT02906618

View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials

NCT01695005Phase 1

A Study of LY3039478 in Participants With Advanced Cancer

Completed

NCT02784795Phase 1

A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors

Terminated

NCT02836600Phase 1

A Study of LY3039478 in Japanese Participants With Advanced Solid Tumors

Completed

NCT02917733Phase 1

A Study of the Absorption, Distribution, Metabolism and Excretion of LY3039478 in Healthy Participants

Completed

NCT02906618Phase 1

Study of LY3039478 in Healthy Participants

Completed

NCT02518113Phase 1

A Study of LY3039478 in Combination With Dexamethasone in Participants With T-ALL/T-LBL

Completed

All 6 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 6